Literature DB >> 9516594

Radiation therapy after prostatectomy: now or later?

S E Schild1.   

Abstract

Patients with pathological stage T3 or T4 prostate cancers who have undetectable prostate-specific antigen (PSA) levels after radical retropubic prostatectomy (RRP) have a substantial risk of recurrence. The first sign of recurrence is a rising PSA level, which precedes clinical evidence of failure by months to years. Adjuvant radiation therapy can significantly reduce the risk of failure in these patients. Patients with rising PSA levels after RRP can be salvaged with radiation therapy. Larger series report that between 30% and 54% of carefully staged patients can be salvaged with radiation therapy alone. It is possible that more patients may be salvaged in the future with the use of combined radiation therapy and hormonal therapy. Although one cannot be certain which approach-adjuvant or salvage radiation therapy- is better, studies are being performed that will help clarify this clinical dilemma. Copyright 1998 W.B. Saunders Company.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9516594     DOI: 10.1016/s1053-4296(98)80009-x

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  2 in total

1.  Adjuvant and salvage radiotherapy after prostatectomy: outcome analysis of 307 patients with prostate cancer.

Authors:  Beatrice Detti; Silvia Scoccianti; Sara Cassani; Samantha Cipressi; Donata Villari; Alberto Lapini; Calogero Saieva; Tommaso Cai; Maurizio Pertici; Irene Giacomelli; Lorenzo Livi; Marco Ceroti; Giulio Nicita; Marco Carini; Giampaolo Biti
Journal:  J Cancer Res Clin Oncol       Date:  2012-09-18       Impact factor: 4.553

Review 2.  Adjuvant and salvage radiotherapy after prostatectomy: a systematic review and meta-analysis.

Authors:  Changhao Chen; Tianxin Lin; Yu Zhou; Doudou Li; Kewei Xu; Zhihua Li; Xinxiang Fan; Guangzheng Zhong; Wang He; Xu Chen; Xianyin He; Jian Huang
Journal:  PLoS One       Date:  2014-08-14       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.